Sign In
Last checked at 
27 Jun 2024 16:49
27 June 2024
Kanabo Group Plc
("Kanabo" or the "Company")
Result of AGM
Kanabo Group Plc (LSE:KNB), a leading health tech company, announces that at the Annual General Meeting ("AGM") held earlier today, eight resolutions were duly passed. The numbers of votes for each resolution are presented below:
Resolution (No. as noted on proxy form) | Total For (i) | Total Against | Withheld (ii) | ||
| No. of votes | % of vote | No. of votes | % of vote | No. of votes |
Resolution 1
| 226,464,519 | 99.86% | 313,881 | 0.14% | 129,393 |
Resolution 2
| 218,146,960 | 96.31% | 8,339,516 | 3.68% | 420,817 |
Resolution 3
| 226,331,517 | 99.83% | 376,111 | 0.17% | 200,165 |
Resolution 4
| 218,268,057 | 96.28% | 8,436,008 | 3.72% | 203,728 |
Resolution 5
| 216,203,853 | 95.36% | 10,500,212 | 4.63% | 203,728 |
Resolution 6
| 216,246,519 | 95.38% | 10,457,546 | 4.61% | 203,728 |
Resolution 7
| 226,256,746 | 99.80% | 447,319 | 0.20% | 203,728 |
Resolution 8
| 155,841,995 | 68.79% | 70,696,796 | 31.21% | 368,502 |
Resolution 9 (iii)
| 155,793,930 | 68.78% | 70,707,021 | 31.% | 406,342 |
(i) The "For" Proxy vote includes those giving the Chair of the AGM discretion
(ii) A vote "Withheld" is not a vote in law and is not included in the proxy votes "For" or "Against" the resolution
(iii) Special resolution
The full text of the resolutions can be found in the Notice of Annual General Meeting, which is available on the Company's website at: https://www.kanabogroup.com/investors/
For further information, please visit http://www.kanabogroup.com/ or contact the following:
Enquiries:
Kanabo Group plc Avihu Tamir, Chief Executive Officer Assaf Vardimon, Chief Financial OfficerIan Mattioli, Non-Executive Chair of the Board
| via Peterhouse Capital +44 (0)20 7469 0930 |
| |
Peterhouse Capital Limited (Financial Adviser and Broker) | +44 (0)20 7469 0930 |
About Kanabo Group Plc
Kanabo Group Plc (LSE:KNB) is a healthtech company committed to revolutionising patient care through its innovative technology platform and disruptive product offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.
Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. The Company is a leader in its field, focusing on improving patient outcomes and providing more accessible healthcare experiences.
In March 2023, Kanabo successfully launched its Pain Clinic, Treat It, under the expert guidance of its technological and product expertise. Treat It initially focuses on chronic pain management using plant-based medicine and treatments that are currently unavailable through traditional channels.
At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.
Visit www.kanabogroup.com for more information.
Follow the stocks
